YOLFTbeta
Schrodinger Inc

Schrodinger Inc

SDGR · NASDAQ · Healthcare / Health Information Services

29.53USD-1.32 (-4.28%)

Price History

Full chart

Market Stats

Previous Close30.85
Open30.71
Day Range28.17 – 30.85
52-Week Range10.95 – 33.78
Volume1.28M
Market Cap2.00B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.74
Dividend Yield0.00%
Beta1.62
50-Day Avg24.34
200-Day Avg16.59

About

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEODr. Ramy Farid Ph.D.
  • Employees850
  • Headquarters1540 Broadway, New York, NY, United States, 10036, USA
  • Websitehttps://www.schrodinger.com

Leadership

  • Dr. Ramy Farid Ph.D.CEO, President & Director · b. 1965
  • Dr. Karen Akinsanya Ph.D.President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships · b. 1968
  • Dr. Richard A. Friesner Ph.D.Co-Founder, Scientific Advisory Chairman and Director · b. 1953
  • Mr. Richie JainExecutive VP, CFO & Treasurer · b. 1985
  • Ms. Yvonne Tran Esq.Corporate Secretary, Chief Legal & People Officer · b. 1971
  • Prof. William Goddard III, Ph.D.Co-Founder & Scientific Advisor
  • Mr. Kenneth Patrick LortonExecutive VP, CTO & COO of Software · b. 1984
  • Ms. Therese AbramsPrincipal Accounting Officer · b. 1984
  • Mr. Shane BraunerExecutive VP & Chief Information Officer · b. 1977
  • Ms. Jaren Irene MaddenChief Corporate Affairs Officer & Head of Investor Relations

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue55.69M66.64M85.54M108.09M137.93M180.96M216.67M207.54M255.87M
Growth (%)-+19.65%+28.37%+26.36%+27.60%+31.19%+19.73%-4.21%+23.29%
Cost of Revenue15.89M23.70M36.45M44.62M72.31M79.93M75.97M75.46M113.25M
Gross Profit39.80M42.94M49.09M63.47M65.62M101.02M140.69M132.08M142.61M
Gross Margin71.46%64.43%57.39%58.72%47.57%55.83%64.93%63.64%55.74%
Operating Expense58.82M70.91M87.81M124.39M177.06M247.84M318.14M341.38M309.51M
Operating Income-19.02M-27.97M-38.72M-60.92M-111.44M-146.82M-177.45M-209.30M-166.90M
Operating Margin-34.15%-41.97%-45.26%-56.35%-80.80%-81.13%-81.90%-100.85%-65.23%
EBITDA-17.34M-25.07M-35.08M-57.26M-97.96M-144.78M48.47M-179.55M-96.30M
EBITDA Margin-31.13%-37.63%-41.00%-52.97%-71.02%-80.01%22.37%-86.51%-37.64%
Net Income-17.39M-28.43M-24.57M-24.46M-100.39M-149.19M40.72M-187.12M-103.27M
Net Income Margin-31.23%-42.66%-28.72%-22.63%-72.78%-82.44%18.79%-90.16%-40.36%
R&D27.67M34.52M39.40M64.69M90.90M126.37M181.77M201.78M173.14M
R&D as % of Total Revenue49.68%51.81%46.06%59.85%65.91%69.84%83.89%97.23%67.67%
Interest Expense0023.77M65.06M22.82M3.00K---
Interest Expense % of Total Revenue0.00%0.00%27.79%60.19%16.54%0.00%---

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets58.02M120.73M155.27M746.26M756.49M688.59M802.96M823.23M726.16M
Total Liabilities103.38M192.29M248.59M122.24M199.40M240.68M254.40M401.78M362.11M
Total Equity-45.36M-71.56M-93.36M624.01M557.07M447.89M548.56M421.44M364.05M
Cash9.96M77.72M25.99M202.30M120.27M90.47M155.31M147.33M230.52M
Total Debt--14.47M11.76M79.87M116.49M127.88M117.83M109.23M
Net Debt-9.96M-77.72M-11.51M-190.53M-40.40M26.02M-27.43M-29.50M-121.29M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.31M-23.71M-26.06M16.76M-70.67M-119.68M-136.73M-157.37M13.90M
Investing Cash Flow2.05M11.19M-53.85M-381.72M-16.81M90.02M193.03M148.84M57.90M
Financing Cash Flow1.13M80.27M28.68M541.27M7.95M2.11M9.05M10.12M2.93M
Capital Expenditure3.70M5.26M1.84M2.54M7.17M8.01M13.40M7.31M1.44M
Free Cash Flow-19.01M-28.97M-27.89M14.22M-77.84M-127.70M-150.14M-164.68M12.46M
FCF to OCF124.17%122.18%107.05%84.85%110.14%106.70%109.80%104.65%89.63%

Earnings

Report DateOct 30, 2019Mar 16, 2020May 13, 2020Aug 10, 2020Nov 12, 2020Mar 4, 2021May 11, 2021Aug 12, 2021Nov 10, 2021Feb 24, 2022May 4, 2022Aug 4, 2022Nov 3, 2022Feb 28, 2023May 4, 2023Aug 2, 2023Nov 1, 2023Feb 28, 2024May 1, 2024Jul 31, 2024Nov 12, 2024Feb 26, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Mar 4, 2026May 5, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.00-0.26-0.20-0.32-0.09-0.08-0.25-0.09-0.29-0.39-0.43-0.49-0.59-0.53-0.19-0.38-0.69-0.38-0.74-0.89-0.63-0.38-0.81-0.64-0.75-0.20-0.57-0.60-0.65
EPS Actual-0.01-1.11-0.22-0.25-0.22-0.18-0.27-0.32-0.38-0.43-0.27-0.17-0.50-0.38-0.23-0.60-0.70-0.41-0.76-0.74-0.87-0.24-0.64-0.65-0.45-0.18-0.620.08-
Surprise--326.92%-10.00%21.88%-144.44%-125.00%-8.00%-255.56%-31.03%-10.26%37.21%65.31%15.25%28.30%-21.05%-57.89%-1.45%-7.89%-2.70%16.85%-38.10%36.84%20.99%-1.56%40.00%7.59%-8.77%113.33%-
Timing-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap2.00B
Enterprise Value1.53B
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.72
Price / Book5.57
EPS-0.74
Book Value4.51
Revenue (TTM)259.04M
Gross Profit (TTM)147.31M
EBITDA-147.58M
Profit Margin-20.98%
Operating Margin-70.55%
Return on Equity-16.17%
Return on Assets-14.44%
Shares Outstanding65.64M
Shares Float57.33M
Beta1.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 25.86
  • Strong Buy
    5
  • Hold
    2

Ownership Breakdown

Institutions
98.04%
Insiders
3.00%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    10.52M14.07%
  • Gates Bill & Melinda Foundation
    6.98M9.33%
  • Rubric Capital Management LP
    6.40M8.56%
  • Vanguard Portfolio Management, LLC
    3.79M5.06%
  • Amova Asset Management Americas, Inc
    2.71M3.62%
  • Sumitomo Mitsui Trust Group Inc
    2.71M3.62%
  • Vanguard Capital Management, LLC
    2.69M3.60%
  • State Street Corp
    2.30M3.07%
  • UBS Asset Mgmt Americas Inc
    2.22M2.97%
  • ARK Investment Management LLC
    2.15M2.88%
  • AQR Capital Management LLC
    1.96M2.62%
  • Geode Capital Management, LLC
    1.47M1.97%
  • Morgan Stanley - Brokerage Accounts
    1.25M1.66%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    3.40M4.54%
  • ARK Genomic Revolution ETF
    2.21M2.96%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.97M2.63%
  • iShares Russell 2000 ETF
    1.51M2.01%
  • Amova ARK Disruptive Innovation A USD
    1.45M1.93%
  • Vanguard Small Cap Index
    1.40M1.88%
  • Amova ARK Pstv Chg Innovt P JPY Acc
    1.00M1.34%